Cargando…

High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021

BACKGROUND: Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time. METHODS: In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dub, Timothée, Solastie, Anna, Hagberg, Lotta, Liedes, Oona, Nohynek, Hanna, Haveri, Anu, Virta, Camilla, Vara, Saimi, Lasander, Mervi, Ekström, Nina, Österlund, Pamela, Lind, Katja, Valtonen, Hanna, Hemmilä, Heidi, Ikonen, Niina, Lukkarinen, Timo, Palmu, Arto A., Melin, Merit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366099/
https://www.ncbi.nlm.nih.gov/pubmed/35966873
http://dx.doi.org/10.3389/fmed.2022.876532
_version_ 1784765483875041280
author Dub, Timothée
Solastie, Anna
Hagberg, Lotta
Liedes, Oona
Nohynek, Hanna
Haveri, Anu
Virta, Camilla
Vara, Saimi
Lasander, Mervi
Ekström, Nina
Österlund, Pamela
Lind, Katja
Valtonen, Hanna
Hemmilä, Heidi
Ikonen, Niina
Lukkarinen, Timo
Palmu, Arto A.
Melin, Merit
author_facet Dub, Timothée
Solastie, Anna
Hagberg, Lotta
Liedes, Oona
Nohynek, Hanna
Haveri, Anu
Virta, Camilla
Vara, Saimi
Lasander, Mervi
Ekström, Nina
Österlund, Pamela
Lind, Katja
Valtonen, Hanna
Hemmilä, Heidi
Ikonen, Niina
Lukkarinen, Timo
Palmu, Arto A.
Melin, Merit
author_sort Dub, Timothée
collection PubMed
description BACKGROUND: Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time. METHODS: In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal and serum samples over 28 days after index case onset. We calculated SAR based on the presence of SARS-CoV-2 neutralizing antibodies (NAb) and assessed the persistence of NAb and IgG antibodies (Ab) against SARS-CoV-2 spike glycoprotein and nucleoprotein. RESULTS: SAR was 45% (39/87), including 35 symptomatic secondary cases. During the initial 28-day follow-up, 62% (80/129) of participants developed NAb. Of those that seroconverted, 90% (63/70), 85% (63/74), and 78% (45/58) still had NAb to early B-lineage SARS-CoV-2 3, 6, and 12 months after the onset of the index case. Anti-spike IgG Ab persisted in 100% (69/69), 97% (72/74), and 93% (55/59) of seroconverted participants after 3, 6, and 12 months, while anti-nucleoprotein IgG Ab levels waned faster, persisting in 99% (68/69), 78% (58/74), and 55% (39/71) of participants, respectively. CONCLUSION: Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. NAb to early B-lineage SARS-CoV-2 persisted for at least a year in most cases.
format Online
Article
Text
id pubmed-9366099
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93660992022-08-12 High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021 Dub, Timothée Solastie, Anna Hagberg, Lotta Liedes, Oona Nohynek, Hanna Haveri, Anu Virta, Camilla Vara, Saimi Lasander, Mervi Ekström, Nina Österlund, Pamela Lind, Katja Valtonen, Hanna Hemmilä, Heidi Ikonen, Niina Lukkarinen, Timo Palmu, Arto A. Melin, Merit Front Med (Lausanne) Medicine BACKGROUND: Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time. METHODS: In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal and serum samples over 28 days after index case onset. We calculated SAR based on the presence of SARS-CoV-2 neutralizing antibodies (NAb) and assessed the persistence of NAb and IgG antibodies (Ab) against SARS-CoV-2 spike glycoprotein and nucleoprotein. RESULTS: SAR was 45% (39/87), including 35 symptomatic secondary cases. During the initial 28-day follow-up, 62% (80/129) of participants developed NAb. Of those that seroconverted, 90% (63/70), 85% (63/74), and 78% (45/58) still had NAb to early B-lineage SARS-CoV-2 3, 6, and 12 months after the onset of the index case. Anti-spike IgG Ab persisted in 100% (69/69), 97% (72/74), and 93% (55/59) of seroconverted participants after 3, 6, and 12 months, while anti-nucleoprotein IgG Ab levels waned faster, persisting in 99% (68/69), 78% (58/74), and 55% (39/71) of participants, respectively. CONCLUSION: Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. NAb to early B-lineage SARS-CoV-2 persisted for at least a year in most cases. Frontiers Media S.A. 2022-07-28 /pmc/articles/PMC9366099/ /pubmed/35966873 http://dx.doi.org/10.3389/fmed.2022.876532 Text en Copyright © 2022 Dub, Solastie, Hagberg, Liedes, Nohynek, Haveri, Virta, Vara, Lasander, Ekström, Österlund, Lind, Valtonen, Hemmilä, Ikonen, Lukkarinen, Palmu and Melin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Dub, Timothée
Solastie, Anna
Hagberg, Lotta
Liedes, Oona
Nohynek, Hanna
Haveri, Anu
Virta, Camilla
Vara, Saimi
Lasander, Mervi
Ekström, Nina
Österlund, Pamela
Lind, Katja
Valtonen, Hanna
Hemmilä, Heidi
Ikonen, Niina
Lukkarinen, Timo
Palmu, Arto A.
Melin, Merit
High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
title High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
title_full High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
title_fullStr High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
title_full_unstemmed High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
title_short High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
title_sort high secondary attack rate and persistence of sars-cov-2 antibodies in household transmission study participants, finland 2020–2021
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366099/
https://www.ncbi.nlm.nih.gov/pubmed/35966873
http://dx.doi.org/10.3389/fmed.2022.876532
work_keys_str_mv AT dubtimothee highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT solastieanna highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT hagberglotta highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT liedesoona highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT nohynekhanna highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT haverianu highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT virtacamilla highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT varasaimi highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT lasandermervi highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT ekstromnina highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT osterlundpamela highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT lindkatja highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT valtonenhanna highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT hemmilaheidi highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT ikonenniina highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT lukkarinentimo highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT palmuartoa highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021
AT melinmerit highsecondaryattackrateandpersistenceofsarscov2antibodiesinhouseholdtransmissionstudyparticipantsfinland20202021